Drug for weight loss lowers type 2 diabetes risk in obese patients

10/11/2013 | MedPage Today (free registration)

Overweight and obese patients who took the weight-loss drug Qsymia, which combines phentermine and topiramate extended release, were 70.5% to 78.7% less likely than those in the placebo group to develop type 2 diabetes, a study found. Patients in the Qsymia arm also showed greater weight loss at 108 weeks compared with the controls, researchers wrote in Diabetes Care.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY